Early detection has always been key in cancer treatment. In a global cancer/tumor profiling market expected to hit $35 billion by 2018, there is a company, Biomark Diagnostics (CSE: BUX), which is developing a diagnostic technique that will identify the presence of cancer earlier than any method to date while the tumor is pre-visible and pre-symptomatic. This means the patient can look forward to significantly greater successful treatment outcomes. Hi, I’m Gaalen Engen, Head of Editorial for Stockhouse Publishing, and I spoke with Biomark Diagnostics founder and CEO, Rashid Ahmed, to get a better idea of the company and its tremendous potential to disrupt a multi-billion medical market. Have a listen.
June 20, 2016